United Cannabis Corp (OTCMKTS:CNAB) a biotechnology firm is committed to advancement of phyto-therapeutic based offerings supported by original technologies for the medical, industrial and pharma markets. They enhance the quality of life by targeting crop based therapeutics.
More recently, the company and Advesa finalized a strategic deal under which Advesa will serve as its product manufacturing facility in California. Advesa was planned and created by the CTO, Tony Verzura, to facilitate the growth of United Cannabis branded items, technologies, and its R&D activities for global partnerships.
Prior to this deal, United Cannabis signed an exclusive licensing contract with Vessel Life Sciences to produce and distribute its offerings, including the Prana Bio Nutrient Medicinals, across Pennsylvania. Vessel Life is dedicated to advancing the application of cannabinoids in treatment, with a focus on the improvement of genetics for medicinal grade strains of cannabinoids-rich cannabis crops for the commonwealth of Pennsylvania’s subject base.
Grounded on the principles of patient-led results, Vessel Science objective is to provide the highest quality of offerings that indisputably reinforce and prove the application of medical pot for patient benefits and health growth.
United Cannabis’ Prana line provides a wide selections of active and raw cannabinoid supplements with numerous delivery processes that have accurately dosed drug from 1 mg to 100 mg. These patient-driven programs and products are designed to assist regulate the endogenous endocannabinoid system, probably the most vital physiological mechanism in maintaining human health. United Cannabis Prana line products are most effective when they are used in combination with the protracted services offered by the A.C.T. Now Plan.
Collin Palmer, the CEO of Vessel Life, reported that there is a robust demand for medicinal cannabis in Pennsylvania, and they plan to become a pioneer in this market. Their exclusive association with United Cannabis and its Prana line will enable them to deliver effective and clean medicine to patients in need once Act 16 is implemented.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: